(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas

Not Applicable

Completed

Brief Summary: This is a prospective study to document the local control rates with SBRT specifically for pulmonary metastases from soft tissue sarcoma. This study will prospectively document acute and late toxicity, quality of life (QoL), tumor control, and survival.

Detailed Description: A total of no more than 20 people are expected to participate in this study at the Medical College of Wisconsin/Froedtert Hospital. Patients will be followed for three years.

The usual treatment for sarcomas that spread to the lungs is to remove the cancer with surgery. Patients who cannot have surgery or prefer not to have surgery, can receive radiation therapy. Standard radiation therapy involves several weeks of daily treatment sessions, although it is not as effective as surgery and may seriously damage normal surrounding lung tissue. Stereotactic body radiation therapy (SBRT) is a radiation treatment that gives fewer but higher doses of radiation than standard radiation. SBRT is used to treat metastases to the lung from many types of cancer but has not been used very often with patients who have metastatic disease to their lungs from sarcomas.

The purpose of this study is to test the possibility of SBRT to the lung for metastatic disease to the lung. This information will be used to find out if there are factors that can predict recovery or outcome of patients with metastatic disease to the lung from sarcoma. SBRT will consist of 1 to 3 treatments per week for a total of 3 to 5 treatments to each tumor until therapy is complete. After SBRT is completed, follow-up exams will occur 4-6 weeks from the completion of radiation treatment, every 3 months in year 1 and every 6 months for 2 years.

Recruitment & Eligibility

Inclusion Criteria

≥18 years of age
Pathologic confirmation of primary soft tissue sarcoma with pathologic or radiographic evidence of pulmonary metastatic disease
No evidence of extra pulmonary progression of disease for 3 months prior to enrollment on study
1-5 pulmonary lesions all ≤5 cm in size
Medically inoperable or declines surgery
Patients may have had previous treatment for pulmonary metastases

Exclusion Criteria

Patients who have uncontrolled extra-pulmonary disease
Pregnant women
Patients who have greater than 5 pulmonary lesions at the time of study enrollment
Patients who have disease progression outside the lungs within 3 months of enrollment on the study
Disease pathology other than sarcoma subtypes
Patients with a history of metastatic disease from a primary other than sarcoma

Arm && Interventions

Group	Intervention	Description
Stereotactic Body Radiation Therapy	SBRT	Arms: Stereotactic Body Radiation Therapy (SBRT) with Adaptive Radiation Therapy (ART) for all patients. A non-randomized study. Patients must have 1-5 pulmonary metastases all less than 5 cm in size. Pathologic confirmation of primary soft tissue sarcoma. All lesions to receive 3-5 fractions to each tumor. Treatments delivered with \> 10 Gy per fraction will have a minimum of 48 hour interfraction interval. For treatments with ≤ 10 Gy per fraction will have a minimum 24 hour interfraction interval. Treatments will be ideally completed over 14 days for 3 fraction treatments and over 21 days for \>5 fraction treatment schedules.

Primary Outcome Measures

Name	Time	Method
Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria.	6 weeks post SBRT	This measure (number of adverse events of grade ≥ 3 by Common Terminology Criteria for Adverse Events (CTCAE) criteria) will provide information regarding the acute toxicity of SBRT for \< 5 pulmonary metastases from soft tissue sarcoma..The CTCAE criteria provide a standardized description of adverse events including guidelines for grading severity. The guidelines can be viewed at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.

Secondary Outcome Measures

Name	Time	Method
Number of Subjects Experiencing Locoregional Recurrences.	3 years	This measure (number of subjects experiencing locoregional recurrences) will provide information regarding locoregional control. Locoregional recurrence means any new or renewed tumor growth of any size observed by an imaging technology that is located at or adjacent to a prior treatment site.